SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
133
|
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
HIV Acquisition and Prevention During Pregnancy and Postpartum (ABSTRACT
27)
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
Systems Vaccinology (ABSTRACT
28)
Bali Pulendran
Stanford University, Stanford, CA, USA
Introduction of Speakers Part 1
Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome (ABSTRACT
151)
Onyema Ogbuagu
Yale University, New Haven, CT, USA
Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor (ABSTRACT
152)
Luise Rogg
ViiV Healthcare, Durham, NC, USA
Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor (ABSTRACT
153)
Paul Benn
ViiV Healthcare, Brentford, UK
Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir (ABSTRACT
154)
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
Questions and Answers Part 1
Introduction of Speakers Part 2
Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs (ABSTRACT
155)
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir (ABSTRACT
156)
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention (ABSTRACT
157)
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial (ABSTRACT
158)
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx (ABSTRACT
159)
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Questions and Answers Part 2
Introduction of Speakers Part 1
Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays (ABSTRACT
142)
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24 (ABSTRACT
143)
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV (ABSTRACT
144)
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature (ABSTRACT
145)
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Questions and Answers Part 1
Introduction of Speakers Part 2
HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia (ABSTRACT
146)
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques (ABSTRACT
147)
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge (ABSTRACT
148)
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs (ABSTRACT
149)
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb (ABSTRACT
150)
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
Questions and Answers Part 2
Introduction of Speakers Part 1
Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening (ABSTRACT
160)
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis (ABSTRACT
161)
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC (ABSTRACT
162)
Amanda D. Castel
The George Washington University, Washington, DC, USA
High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation (ABSTRACT
163)
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
Questions and Answers Part 1
Introduction of Speakers Part 2
The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco (ABSTRACT
164)
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV (ABSTRACT
165)
Namwa Wongkalasin
Imperial College London, London, UK
Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT (ABSTRACT
166)
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
Questions and Answers Part 2
Introduction of Speakers Part 1
Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses (ABSTRACT
133)
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly (ABSTRACT
134)
Ivy K. Hughes
Boston University, Boston, MA, USA
Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore (ABSTRACT
135)
Yao Shen
University of Oxford, Oxford, UK
Visualizing the Cell Biology of HIV Latency and Reactivation (ABSTRACT
136)
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
Questions and Answers Part 1
Introduction of Speakers Part 2
Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes (ABSTRACT
137)
Amare Eshetu
Yale University, New Haven, CT, USA
Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells (ABSTRACT
138)
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa (ABSTRACT
139)
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
133
|
